NCT03713944View on ClinicalTrials.gov

Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 15, 2018

Primary Completion Date

December 16, 2021

Study Completion Date

December 16, 2021

Conditions
NSCLC Stage IVNSCLC, Recurrent
Interventions
DRUG

Carboplatin

Carboplatin, AUC 5

DRUG

Pemetrexed

Pemetrexed 500mg/m2

DRUG

Atezolizumab

Atezolizumab 1200mg

DRUG

Bevacizumab

Bevacizumab 15mg/kg

Trial Locations (7)

22908

University of Virginia Health System, Charlottesville

46202

Indiana Univeristy Melvin and Bren Simon Cancer Center, Indianapolis

52242

University of Iowa Hospitals and Clinics, Iowa City

53188

ProHealth Care, Waukesha

53705

University of Wisconsin, Madison

60612

University of Illinois Cancer Center, Chicago

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Nasser Hanna

OTHER